Analysis

  • The Fight Against Drug Resistance

    Drugs are becoming a victim of their own success with resistant strains of diseases becoming increasingly common. Dr Gareth Evans looks at the strategies being taken to combat this worrying...

  • Tracing Supply Chain Standards

    For a water-tight supply chain, track and trace standards must begin at the very earliest stages of clinical trials. With industry experts meeting in June at VIB's GMP and GCP...

  • No Pill for Rough Seas

    The pharmaceutical sector is facing unprecedented challenges caused by the economic downturn. President Obama's planned overhaul of the US healthcare system is also having considerable effect. Datamonitor findings show that...

  • Transforming Tomorrow’s Clinical Trials

    Ensuring maximum exposure to molecule has taken late-stage clinical trials down a costly and time-consuming path. With two major VIB events being held in June 2009 to advance the clinical...

  • Preparing for a Pandemic

    Behind the scenes, UK institutions are working together to stop the spread of H1N1 swine flu as best they can. Natalie Coomber reports on the steps taken so far.

  • Creating the Cancer Cure

    Cancer therapies are big business in the pharmaceutical trade. With industry experts meeting in May at VIB pharma's Next Generation Targeted Cancer Therapies event, Natalie Coomber looks at the treatments...

  • Swine Flu is Sweet Pill for Roche and GSK

    Shares in GSK and Roche continue to rocket as their drugs Tamiflu and Relenza are used in the fight against swine flu. Natalie Coomber looks at whether governments are choosing...

  • Swine Flu – Know the Facts

    The world is in a state of concern that the latest strain of swine flu could soon turn into a global pandemic. We examine the history of the virus, the...

  • Is Barack the Cure-All for Pharmaceutical Health?

    Healthcare reform was a key component of Obama's winning campaign, with affordable healthcare coverage its cornerstone. So where exactly do the controversial plans stand with the pharmaceutical sector? Nicola Boyes...

Close
Close
Close

Go Top